SOMALOGIC INC (SLGC) Fundamental Analysis & Valuation

NASDAQ:SLGC • US83444K1051

Current stock price

2.1 USD
-0.1 (-4.55%)
At close:
2 USD
-0.1 (-4.76%)
After Hours:

This SLGC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SLGC Profitability Analysis

1.1 Basic Checks

  • SLGC had negative earnings in the past year.
  • SLGC had a negative operating cash flow in the past year.
SLGC Yearly Net Income VS EBIT VS OCF VS FCFSLGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of SLGC (-23.08%) is worse than 68.85% of its industry peers.
  • SLGC has a Return On Equity (-26.25%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -23.08%
ROE -26.25%
ROIC N/A
ROA(3y)-17.05%
ROA(5y)N/A
ROE(3y)-20.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLGC Yearly ROA, ROE, ROICSLGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

  • SLGC has a Gross Margin (41.14%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of SLGC has grown nicely.
  • The Profit Margin and Operating Margin are not available for SLGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.12%
GM growth 5YN/A
SLGC Yearly Profit, Operating, Gross MarginsSLGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 50 -50 -100 -150

7

2. SLGC Health Analysis

2.1 Basic Checks

  • SLGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SLGC has been increased compared to 1 year ago.
  • There is no outstanding debt for SLGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLGC Yearly Shares OutstandingSLGC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M
SLGC Yearly Total Debt VS Total AssetsSLGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 2.03 indicates that SLGC is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • SLGC has a Altman-Z score of 2.03. This is comparable to the rest of the industry: SLGC outperforms 47.54% of its industry peers.
  • There is no outstanding debt for SLGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.03
ROIC/WACCN/A
WACC12.33%
SLGC Yearly LT Debt VS Equity VS FCFSLGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M 400M 600M

2.3 Liquidity

  • SLGC has a Current Ratio of 17.77. This indicates that SLGC is financially healthy and has no problem in meeting its short term obligations.
  • SLGC has a better Current ratio (17.77) than 95.08% of its industry peers.
  • A Quick Ratio of 17.27 indicates that SLGC has no problem at all paying its short term obligations.
  • SLGC's Quick ratio of 17.27 is amongst the best of the industry. SLGC outperforms 95.08% of its industry peers.
Industry RankSector Rank
Current Ratio 17.77
Quick Ratio 17.27
SLGC Yearly Current Assets VS Current LiabilitesSLGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 200M 400M 600M

4

3. SLGC Growth Analysis

3.1 Past

  • SLGC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
  • SLGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.73%.
  • Measured over the past years, SLGC shows a very strong growth in Revenue. The Revenue has been growing by 44.77% on average per year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-19.73%
Revenue growth 3Y44.77%
Revenue growth 5YN/A
Sales Q2Q%-47.13%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.80% on average over the next years.
  • The Revenue is expected to grow by 11.84% on average over the next years. This is quite good.
EPS Next Y-2.43%
EPS Next 2Y3.89%
EPS Next 3Y4.51%
EPS Next 5Y3.8%
Revenue Next Year-12.14%
Revenue Next 2Y1.69%
Revenue Next 3Y7.5%
Revenue Next 5Y11.84%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SLGC Yearly Revenue VS EstimatesSLGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
SLGC Yearly EPS VS EstimatesSLGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.2 -0.4 -0.6

0

4. SLGC Valuation Analysis

4.1 Price/Earnings Ratio

  • SLGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SLGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLGC Price Earnings VS Forward Price EarningsSLGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLGC Per share dataSLGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y4.51%

0

5. SLGC Dividend Analysis

5.1 Amount

  • SLGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SLGC Fundamentals: All Metrics, Ratios and Statistics

SOMALOGIC INC

NASDAQ:SLGC (1/5/2024, 8:26:28 PM)

After market: 2 -0.1 (-4.76%)

2.1

-0.1 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-08
Earnings (Next)03-26
Inst Owners0.05%
Inst Owner Change0%
Ins Owners0.46%
Ins Owner Change0%
Market Cap396.23M
Revenue(TTM)81.73M
Net Income(TTM)-130.38M
Analysts80
Price Target4.01 (90.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.28%
Min EPS beat(2)17.77%
Max EPS beat(2)30.8%
EPS beat(4)3
Avg EPS beat(4)10.01%
Min EPS beat(4)-21.38%
Max EPS beat(4)30.8%
EPS beat(8)7
Avg EPS beat(8)20.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.4%
Min Revenue beat(2)1.23%
Max Revenue beat(2)5.58%
Revenue beat(4)4
Avg Revenue beat(4)7.3%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.55%
Revenue beat(8)6
Avg Revenue beat(8)11.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.46%
EPS NY rev (1m)0%
EPS NY rev (3m)11.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.85
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.43
BVpS2.63
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.08%
ROE -26.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.14%
FCFM N/A
ROA(3y)-17.05%
ROA(5y)N/A
ROE(3y)-20.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.12%
GM growth 5YN/A
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.2%
Cap/Sales 4.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.77
Quick Ratio 17.27
Altman-Z 2.03
F-Score3
WACC12.33%
ROIC/WACCN/A
Cap/Depr(3y)139.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-2.43%
EPS Next 2Y3.89%
EPS Next 3Y4.51%
EPS Next 5Y3.8%
Revenue 1Y (TTM)-19.73%
Revenue growth 3Y44.77%
Revenue growth 5YN/A
Sales Q2Q%-47.13%
Revenue Next Year-12.14%
Revenue Next 2Y1.69%
Revenue Next 3Y7.5%
Revenue Next 5Y11.84%
EBIT growth 1Y-0.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.1%
EBIT Next 3Y14.46%
EBIT Next 5Y7.07%
FCF growth 1Y-359.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-444.14%
OCF growth 3YN/A
OCF growth 5YN/A

SOMALOGIC INC / SLGC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SOMALOGIC INC?

ChartMill assigns a fundamental rating of 3 / 10 to SLGC.


What is the valuation status of SOMALOGIC INC (SLGC) stock?

ChartMill assigns a valuation rating of 0 / 10 to SOMALOGIC INC (SLGC). This can be considered as Overvalued.


Can you provide the profitability details for SOMALOGIC INC?

SOMALOGIC INC (SLGC) has a profitability rating of 1 / 10.


Can you provide the financial health for SLGC stock?

The financial health rating of SOMALOGIC INC (SLGC) is 7 / 10.